D-0688-2022 Class II Terminated

Recalled by Teligent Pharma, Inc. — Buena, NJ

FDA drug recall D-0688-2022 was initiated by Teligent Pharma, Inc. on Mar 15, 2022 and is designated Class II. Reason for recall: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program. The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 35,185 tubes.

Recall details

Product Type
Drugs
Report Date
Mar 30, 2022
Initiation Date
Mar 15, 2022
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
35,185 tubes

Product description

Halobetasol Propionate Ointment, 0.05%, Net Wt. 50 grams tube, Rx only, Manufactured for: SOLA Pharmaceuticals, Baton Rouge, LA 70809, NDC 70512-033-50.

Reason for recall

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Batch: 15128, Exp. 2/28/2022; 15721, Exp. 6/30/2022; 16171, Exp. 10/31/2022; 16819, Exp. 4/30/2023; 17124, Exp. 7/31/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0688-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0688-2022. Report a data issue: hello@regdatalab.com.